Nyxoah’s Genio Therapy Sees Major Medicare Reimbursement Boost for 2026

Nyxoah SA has announced a significant increase in Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy starting in 2026. According to the final ruling from the Centers for Medicare & Medicaid Services (CMS), payments for the procedure, identified by CPT code 64568, will rise by approximately 48%, bringing the total reimbursement to around $45,000 effective January 1, 2026.

This increase reflects a broader commitment by Medicare to enhance access to innovative medical treatments. The decision is particularly important for patients suffering from obstructive sleep apnea, a condition that affects millions globally. The Genio therapy offers a groundbreaking solution by stimulating the hypoglossal nerve, helping to keep the airway open during sleep.

Impact on Patients and Healthcare Providers

The substantial reimbursement increase is expected to have a positive impact on both patients and healthcare providers. For patients, this enhancement in coverage will likely lead to greater accessibility to the Genio therapy. Many individuals may find relief from sleep apnea symptoms without the need for continuous positive airway pressure (CPAP) devices or invasive surgeries.

Healthcare providers will also benefit from the increased reimbursement rates, enabling them to invest in advanced technologies and improve patient care. This financial support could encourage more hospitals and clinics to adopt Genio therapy as a viable treatment option.

Nyxoah’s Chief Executive Officer, Bernard Schneider, expressed optimism about the ruling, stating, “This increase signifies a major step towards making our innovative therapy more accessible to the patients who need it most.” The company believes that increased reimbursement rates will facilitate broader patient awareness and acceptance of the treatment.

Future Prospects for Nyxoah

Looking ahead, Nyxoah aims to expand its presence in the global health market. The increased Medicare reimbursement is a critical milestone for the company, potentially paving the way for similar adjustments in other international healthcare systems.

The company has plans to conduct further clinical studies and trials to enhance the efficacy of the Genio therapy and gather more data to support its benefits. As reimbursement rates improve, Nyxoah is well-positioned to capitalize on the growing demand for effective sleep apnea treatments.

In summary, the decision by CMS to raise Medicare reimbursement for Genio therapy marks a pivotal moment for Nyxoah SA. With the increase set for January 1, 2026, patients can expect improved access to a leading-edge treatment for sleep apnea, while healthcare providers gain financial support to deliver these innovative therapies.